CL2007001689A1 - Formas cristalinas sustancialmente puras de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida; composicion farmaceutica, util para tratar una enfermedad que responde a una inhibicion de la actividad de cinasa de prot - Google Patents
Formas cristalinas sustancialmente puras de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida; composicion farmaceutica, util para tratar una enfermedad que responde a una inhibicion de la actividad de cinasa de protInfo
- Publication number
- CL2007001689A1 CL2007001689A1 CL200701689A CL2007001689A CL2007001689A1 CL 2007001689 A1 CL2007001689 A1 CL 2007001689A1 CL 200701689 A CL200701689 A CL 200701689A CL 2007001689 A CL2007001689 A CL 2007001689A CL 2007001689 A1 CL2007001689 A1 CL 2007001689A1
- Authority
- CL
- Chile
- Prior art keywords
- methyl
- substantiely
- propenamide
- indol
- illness
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80451706P | 2006-06-12 | 2006-06-12 | |
US88322407P | 2007-01-03 | 2007-01-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007001689A1 true CL2007001689A1 (es) | 2008-05-16 |
Family
ID=38832679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200701689A CL2007001689A1 (es) | 2006-06-12 | 2007-06-11 | Formas cristalinas sustancialmente puras de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida; composicion farmaceutica, util para tratar una enfermedad que responde a una inhibicion de la actividad de cinasa de prot |
Country Status (29)
Country | Link |
---|---|
US (1) | US7989494B2 (es) |
EP (2) | EP2086930A2 (es) |
JP (3) | JP2009540006A (es) |
KR (4) | KR20150082690A (es) |
CN (1) | CN102584673B (es) |
AR (1) | AR061297A1 (es) |
AU (1) | AU2007257881B2 (es) |
BR (1) | BRPI0712993A2 (es) |
CA (1) | CA2650263A1 (es) |
CL (1) | CL2007001689A1 (es) |
CR (1) | CR10440A (es) |
EA (1) | EA017984B1 (es) |
EC (1) | ECSP088976A (es) |
GE (1) | GEP20115175B (es) |
GT (1) | GT200800280A (es) |
IL (1) | IL195015A (es) |
MA (1) | MA30511B1 (es) |
ME (1) | ME00529B (es) |
MX (1) | MX2008015900A (es) |
MY (1) | MY149337A (es) |
NI (1) | NI200800306A (es) |
NO (1) | NO20090135L (es) |
PE (1) | PE20080852A1 (es) |
PH (1) | PH12012501725A1 (es) |
SM (1) | SMP200900001B (es) |
TN (1) | TNSN08495A1 (es) |
TW (2) | TWI515179B (es) |
UY (1) | UY30406A1 (es) |
WO (1) | WO2007146716A2 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GEP20105125B (en) * | 2006-06-12 | 2010-11-25 | Novartis Ag | Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl) ethyl] amino] methyl] phenyl]-2e-2-propenamide |
RU2009130457A (ru) * | 2007-01-10 | 2011-02-20 | Новартис АГ (CH) | Составы ингибиторов дезацетилазы |
WO2017032281A1 (zh) * | 2015-08-21 | 2017-03-02 | 苏州晶云药物科技有限公司 | 帕比司他乳酸盐的新晶型 |
CN106866491B (zh) * | 2015-12-10 | 2021-12-10 | 江苏豪森药业集团有限公司 | 帕比司他乳酸盐晶型ⅰ及其制备方法和用途 |
CN106866492B (zh) * | 2015-12-10 | 2021-11-26 | 江苏豪森药业集团有限公司 | 帕比司他乳酸盐晶型ii及其制备方法和用途 |
WO2018092151A1 (en) * | 2016-11-21 | 2018-05-24 | Msn Laboratories Private Limited, R&D Center | Process for the preparation of 2-(e)-n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl) ethyl]amino]methyl]phenyl]-2-propenamide 2-hydroxypropanoic acid (1:1) and its polymorphs thereof |
WO2018163114A1 (en) * | 2017-03-10 | 2018-09-13 | Shilpa Medicare Limited | Amorphous panobinostat and its lactate salt |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
CA3150303A1 (en) * | 2019-08-20 | 2021-02-25 | Ono Pharmaceutical Co., Ltd. | Salt and crystal form of compound having agonistic activity to s1p5 receptor |
GB201913121D0 (en) | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
GB201913124D0 (en) | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
GB201913122D0 (en) | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
NZ544689A (en) | 2001-11-06 | 2007-08-31 | Novartis Ag | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination |
US20050227300A1 (en) | 2001-12-07 | 2005-10-13 | Atadja Peter W | Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors |
AU2004241729A1 (en) | 2003-05-21 | 2004-12-02 | Novartis Ag | Combination of histone deacetylase inhibitors with chemotherapeutic agents |
WO2005013958A1 (en) | 2003-08-07 | 2005-02-17 | Novartis Ag | Histone deacetylase inhibitors as immunosuppressants |
US20080085902A1 (en) | 2003-09-23 | 2008-04-10 | Guido Bold | Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent |
GEP20105125B (en) | 2006-06-12 | 2010-11-25 | Novartis Ag | Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl) ethyl] amino] methyl] phenyl]-2e-2-propenamide |
-
2007
- 2007-06-07 EP EP07798194A patent/EP2086930A2/en not_active Withdrawn
- 2007-06-07 SM SM200900001T patent/SMP200900001B/it unknown
- 2007-06-07 CN CN201210014735.0A patent/CN102584673B/zh active Active
- 2007-06-07 MX MX2008015900A patent/MX2008015900A/es active IP Right Grant
- 2007-06-07 BR BRPI0712993-9A patent/BRPI0712993A2/pt not_active Application Discontinuation
- 2007-06-07 EP EP11183770A patent/EP2409967A1/en not_active Withdrawn
- 2007-06-07 ME MEP-2008-876A patent/ME00529B/me unknown
- 2007-06-07 KR KR1020157017416A patent/KR20150082690A/ko not_active Application Discontinuation
- 2007-06-07 AU AU2007257881A patent/AU2007257881B2/en not_active Ceased
- 2007-06-07 US US12/302,564 patent/US7989494B2/en active Active
- 2007-06-07 EA EA200802383A patent/EA017984B1/ru not_active IP Right Cessation
- 2007-06-07 KR KR1020147030218A patent/KR20140142335A/ko not_active Application Discontinuation
- 2007-06-07 GE GEAP200711011A patent/GEP20115175B/en unknown
- 2007-06-07 CA CA002650263A patent/CA2650263A1/en not_active Abandoned
- 2007-06-07 JP JP2009515573A patent/JP2009540006A/ja active Pending
- 2007-06-07 KR KR1020087030229A patent/KR20090015968A/ko not_active Application Discontinuation
- 2007-06-07 KR KR1020167006197A patent/KR20160032264A/ko not_active Application Discontinuation
- 2007-06-07 MY MYPI20084896A patent/MY149337A/en unknown
- 2007-06-07 WO PCT/US2007/070561 patent/WO2007146716A2/en active Application Filing
- 2007-06-08 TW TW103124314A patent/TWI515179B/zh not_active IP Right Cessation
- 2007-06-08 AR ARP070102499A patent/AR061297A1/es not_active Application Discontinuation
- 2007-06-08 TW TW096120847A patent/TWI453196B/zh not_active IP Right Cessation
- 2007-06-08 PE PE2007000724A patent/PE20080852A1/es not_active Application Discontinuation
- 2007-06-11 CL CL200701689A patent/CL2007001689A1/es unknown
- 2007-06-11 UY UY30406A patent/UY30406A1/es not_active Application Discontinuation
-
2008
- 2008-10-30 IL IL195015A patent/IL195015A/en active IP Right Grant
- 2008-11-13 CR CR10440A patent/CR10440A/es not_active Application Discontinuation
- 2008-11-21 NI NI200800306A patent/NI200800306A/es unknown
- 2008-11-28 TN TNP2008000495A patent/TNSN08495A1/en unknown
- 2008-12-10 GT GT200800280A patent/GT200800280A/es unknown
- 2008-12-12 EC EC2008008976A patent/ECSP088976A/es unknown
- 2008-12-12 MA MA31470A patent/MA30511B1/fr unknown
-
2009
- 2009-01-09 NO NO20090135A patent/NO20090135L/no not_active Application Discontinuation
-
2012
- 2012-08-29 PH PH12012501725A patent/PH12012501725A1/en unknown
-
2013
- 2013-04-15 JP JP2013085093A patent/JP2013139476A/ja active Pending
-
2015
- 2015-06-24 JP JP2015127007A patent/JP2015164968A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007001689A1 (es) | Formas cristalinas sustancialmente puras de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida; composicion farmaceutica, util para tratar una enfermedad que responde a una inhibicion de la actividad de cinasa de prot | |
BRPI0810893A2 (pt) | Uso de inibidor de tnf-alfa a um anti-histamínico para tratar rinite alérgica e conjuntivite, e composição farmacêutica compreendendo os referidos compostos. | |
CL2007001692A1 (es) | Sal de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida; composicion farmaceutica, util para tratar una enfermedad que responde a una inhibicion de la actividad de cinasa de proteina. | |
PE20100083A1 (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
BRPI0716838A2 (pt) | combinaÇÕes de inibidores de histona deacetilase especÍfica de classe i com inibidores de proteosome | |
CL2007002930A1 (es) | Un compuesto 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridin-2-carboxamida monohidratado; proceso de preparacion; composicion y combinacion farmaceutica; y uso para el tratamiento de trastornos hiperproliferati | |
DK2332909T3 (da) | Hydroxybenzamidderivater og deres anvendelse som inhibitorer af hsp90 | |
SI2004607T1 (sl) | Derivati (4-(4-(6-trifluorometil-piridin-3-ilamino)-N-vsebujoče-heteroaril)- fenil)-cikloheksil)-ocetne kisline in farmacevtske uporabe le-teh | |
NO20092535L (no) | Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol | |
CL2007000918A1 (es) | Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica. | |
HK1126495A1 (en) | Process for making salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3- yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide n--3-[4-[[[2-(2--1h--3-)]]]]-2e-2- | |
SV2010003529A (es) | Composicion de zibotentan que contiene manitol y/o celulosa microcristalina | |
CL2007002329A1 (es) | Compuestos derivados de 5,6-bisaril-2-piridin carboxamida, inhibidores de urotensina ii; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar y/o prevenir insuficiencia cardiaca congestiva, is | |
BRPI0809288A2 (pt) | Formulações farmacêuticas auto-precipitação para a liberação modificada de um princípio ativo | |
DK2094699T3 (da) | Hidtil ukendte imidazolonderivater, fremstilling deraf som lægemidler, farmaceutiske præparater og anvendelse deraf som hæmmere af proteinkinaser, især cdc7 | |
ZA200809651B (en) | Process for making salts of N-hydroxy-3[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide | |
ZA200809383B (en) | Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl] amino]methyl]phenyl]-2E-2propenamide | |
CL2007002817A1 (es) | Modificacion cristalina del compuesto 4-{[(6-cloropirid-3-il)metil](metil)amino}furano-2(5h)-ona; composicion; uso de dicho compuesto; y procedimiento para combatir insectos indeseados. | |
AR063895A1 (es) | Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento de la leucomalacia periventricular | |
NO20091862L (no) | N-(3-bensyl) -2, 2- (bis-fenyl) - propan-1-amin derivativer som CETP inhibitorer for behandlingen av atherosclerose and cardiovaskulaere sykdommer | |
BRPI0924198A2 (pt) | combinação de ingredientes ativos contendo um fármaco anti-inflamtório não esteroidal e um derivado de colchicosida | |
DK2032533T3 (da) | Fremgangsmåde til fremstilling af N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamid samt udgangsmaterialer dertil | |
CY1117493T1 (el) | Αλατα του ν-υδροξυ-3-[4-[[[2-(2-μεθυλ-1η-ινδολ-3-υλ)αιθυλ]αμινο]μεθυλο]φαινυλο]-2ε-2-προπεναμιδιου | |
CL2007002102A1 (es) | Uso de pramipexol y meloxicam para tratar el dolor; y composicion farmaceutica que los comprende. | |
AR057933A1 (es) | Composicion farmaceutica despigmentante que comprende n-(2-((3-(4- bromofenil)- 2- propenil ) amino) etil) -5- isoquinolinsulfonamida (h89) |